Care Access - South Indianapolis

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease3 trials
• Chronic kidney disease1 trial
• Coronary artery disease1 trial
• Heart failure1 trial
• Obesity1 trial
• Peripheral artery disease1 trial
• Stroke1 trial
• Type 2 diabetes1 trial

Phase

• Phase 34 trials

Status

• Active, not recruiting3 trials
• Recruiting1 trial

Lead sponsor

• Eli Lilly and Company4 trials

Running trials

• Recruiting

  A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

  NCT07602582· Phase 3· Eli Lilly and Company· Source

  Contact: Gigi Lefebvre (principal investigator)

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease1 recruiting